2016-02

Dietary administration of a commercial mixed-species probiotic improves growth performance and modulates the intestinal immunity of tilapia, *Oreochromis niloticus*

Standen, BT

<http://hdl.handle.net/10026.1/4258>

10.1016/j.fsi.2015.11.037

Fish & Shellfish Immunology

Elsevier BV

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Accepted Manuscript

Dietary administration of a commercial mixed-species probiotic improves growth performance and modulates the intestinal immunity of tilapia, *Oreochromis niloticus*

B.T. Standen, D.L. Peggs, M.D. Rawling, A. Foey, S.J. Davies, G.A. Santos, D.L. Merrifield

PII: S1050-4648(15)30256-4

DOI: [10.1016/j.fsi.2015.11.037](https://doi.org/10.1016/j.fsi.2015.11.037)

Reference: YFSIM 3719

To appear in: *Fish and Shellfish Immunology*

Received Date: 13 July 2015

Revised Date: 30 October 2015

Accepted Date: 29 November 2015

Please cite this article as: Standen BT, Peggs DL, Rawling MD, Foey A, Davies SJ, Santos GA, Merrifield DL, Dietary administration of a commercial mixed-species probiotic improves growth performance and modulates the intestinal immunity of tilapia, *Oreochromis niloticus*, *Fish and Shellfish Immunology* (2016), doi: 10.1016/j.fsi.2015.11.037.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Dietary administration of a commercial mixed-species probiotic improves growth performance and modulates the intestinal immunity of tilapia, *Oreochromis niloticus*

B. T. Standen^{a*}, D. L. Peggs^a, M. D. Rawling^a, A. Foey^b, S. J. Davies^c, G. A. Santos^d, D. L. Merrifield^{a*}

^a Aquaculture and Fish Nutrition Research Group, School of Biological Sciences and ^b School of Biomedical and Healthcare Sciences, Plymouth University, Drake Circus, Plymouth, Devon PL4 8AA, UK.

^c Department Animal Production, Welfare and Veterinary Science, Harper Adams University, Newport TF10 8NB, UK.

^d Biomin Holding GmbH, Industriestrasse 21, 3130 Herzogenburg, Austria

* Corresponding authors: benedict.standen@yahoo.co.uk; Daniel.merrifield@plymouth.ac.uk

Abstract

The growth performance, immunological status, intestinal morphology and microbiology of tilapia, *Oreochromis niloticus*, were investigated after dietary administration of the commercial probiotic AquaStar[®] Growout. Tilapia (29.02 ± 0.33g) were split into five treatments; control (CON), 1.5g kg⁻¹ probiotic (PRO-1.5), 3g kg⁻¹ probiotic (PRO-3), pulsed probiotic feeding (PRO-PULSE) or an initial probiotic feed followed by control feeding (PRO-INI). After six weeks of experimental feeding, fish fed PRO-3 displayed significantly higher final weight, weight gain and SGR compared to the CON or PRO-INI treatments. Supplementation of the probiotic at this dose induced an up-regulation of intestinal caspase-3, PCNA and HSP70 mRNA levels compared to the CON fed fish. Immuno-modulatory

pathways were also affected; significantly higher expression of TLR2, pro-inflammatory genes TNF α and IL-1 β , and anti-inflammatory genes IL-10 and TGF β suggest that the probiotic may potentiate a higher state of mucosal tolerance and immuno-readiness. Histological appraisal revealed significantly higher numbers of intraepithelial leucocytes in the intestine of PRO-3 fed fish compared with treatments CON, PRO-PULSE and PRO-INI but not PRO-1.5. Additionally, fish receiving PRO-3 had a significantly higher abundance of goblet cells in their mid-intestine when compared with fish from all other treatments. Together, these data suggest that continuous provision of AquaStar[®] Growout at 3g kg⁻¹ can improve tilapia growth and elevate the intestinal immunological status of the host.

Keywords: probiotic; tilapia; fish; immunity; gene expression; growth performance; histology, intestinal microbiology.

1 Introduction

Aquaculture continues to be the fastest growing animal protein production industry [1]. As a result of extensive research, probiotics are becoming an increasingly popular choice as a prophylactic approach to avoid disease and improve health and production of farmed fish, including tilapia.

A number of probiotic investigations have focused on growth benefits in tilapia, with many studies reporting positive results after probiotic supplementation [2-8]. As well as strong growth performance, it is important that fish are healthy and capable of mounting an effective immune response when exposed to pathogens. The gastrointestinal (GI) tract plays an important role in the mucosal barrier function. Not only does it serve as a physico-chemical

barrier against invading pathogens, there are also tolerance mechanisms in place which allow the residence of commensal and mutualistic microbes [9]. Probiotics can have beneficial effects on the gut-associated lymphoid tissues (GALT). These benefits can manifest themselves within the intestine by means of reinforcing barrier defences by elevating populations of intra epithelial leucocytes and goblet cells and also by inducing the expression of pro-inflammatory cytokines (e.g. $\text{TNF}\alpha$, $\text{IL-1}\beta$), thus maintaining the capacity of recognising and responding to pathogens, and regulatory cytokines (e.g. $\text{TGF}\beta$, IL-10) for the maintenance of mucosal tolerance [10-15]. These cytokines are the end products of complex molecular pathways which are initiated by toll-like receptors (TLR's) recognising their corresponding microbe associated molecular pattern (MAMP) [16]. Probiotic supplementation can up-regulate the expression of intestinal TLR3 in Atlantic salmon, *Salmo salar*, and intestinal TLR2 and TLR5 in grouper, *Epinephelus coioides*, with a corresponding induction of intestinal $\text{IL-1}\beta$, $\text{TNF}\alpha$, IL-8 and $\text{TGF}\beta$ expression [17, 18].

Currently, there are multiple probiotic formulations commercially available. It is essential that probiotic candidates are evaluated for efficacy and the dosage and feeding regime should be optimised [19]. The current investigation aimed to evaluate multiple doses and feeding regimes of a commercially available multi-species probiotic, AquaStar® Growout (a mix of *Bacillus subtilis*, *Enterococcus faecium*, *Lactobacillus reuteri* and *Pediococcus acidilactici* at $1 \times 10^9 \text{ CFU g}^{-1}$), on tilapia growth performance, intestinal integrity, intestinal microbiology and intestinal immunity.

2 *Materials and methods*

2.1 *Experimental design and dietary preparation*

All experimental work involving fish was conducted under the Home Office project licence PPL30/2644 and was in accordance with the Animals (Scientific Procedures) Act 1986 and the Plymouth University Ethical Committee.

Three iso-nitrogenous and iso-lipidic diets were formulated using Feedsoft Professional[®] according to the known requirements of tilapia [20] (Table 1). Dry ingredients were mixed in small batches to ensure a homogenous mix before adding the oil and warm water in a Hobart food mixer (Hobart Food equipment, Australia) to form a consistency suitable for cold press extrusion (PTM P6 extruder, Plymouth, UK) to produce 2mm pellets. The lyophilised probiotic (AquaStar[®] Growout; Biomin GmbH) was added at the expense of corn starch and the basal diet void of the probiotic served as a control diet. Diets were dried for 24 hours in an air convection oven set to 44°C, broken up by hand and stored in refrigerated air tight containers prior to use. The dietary proximate composition was analysed using AOAC protocols [21] (Table 1). Probiotic viability was checked using selective media (de Man, Rogosa and Sharpe (MRS) media, *Bacillus* selective agar and Slanetz and Bartley media for *Lactobacillus/Pediococcus*, *Bacillus* and *Enterococcus* spp., respectively) by spread plating 10-fold serial dilutions and counting statistically viable plates (i.e. 20-200 colonies). Fresh diets were produced at the trial midpoint to ensure high probiotic viability.

Nile tilapia, *Oreochromis niloticus*, (Fishgen Ltd., Swansea, UK), were transferred to the Aquaculture and Fish Nutrition Research Aquarium, Plymouth University, UK where they were allowed six weeks of acclimation. Five hundred tilapia were randomly distributed to ten 150L fibreglass tanks (50 fish per tank; average weight = $29.02 \pm 0.33\text{g}$; $n = 2$). Treatments were as follows; control (basal diet void of AquaStar[®] Growout), low probiotic dose

(continuous feeding of the basal diet supplemented with AquaStar® Growout at 1.5g kg⁻¹), high probiotic dose (continuous feeding of the basal diet supplemented with AquaStar® Growout at 3 g kg⁻¹), probiotic pulse feeding (alternating weekly between AquaStar® Growout feeding at 1.5g kg⁻¹ and control feeding) and lastly initial probiotic feeding (first two weeks AquaStar® Growout feeding at 1.5g kg⁻¹ followed by remainder of the trial on the control diet). Diet codes were assigned for ease of analysis (Table 2). Fish were fed experimental diets for six weeks at a rate of 1- 5% biomass per day in four equal rations (all treatments received the same % input each day); higher feeding rates were provided at the beginning of the trial but this was decreased incrementally during the trial as fish grew larger and their appetite decreased. Daily feed was adjusted on a weekly basis by batch weighing following a 24 hour starvation period. Fish were held at 28 ± 1°C with a 12:12 h light: dark photoperiod. Water quality was monitored daily and maintained at pH = 6.5 ± 0.5 (adjusted with NaHCO₃ as necessary) and dissolved oxygen > 6.0 mg l⁻¹. Ammonium, nitrite and nitrate levels were monitored weekly (0.08 ± 0.02, 0.15 ± 0.05 and 18.30 ± 3.30 mg l⁻¹, respectively) and regular water changes prevented the accumulation of these compounds as well as preventing background build-up of probiotics.

2.2 Growth performance and carcass composition

Growth performance and feed utilisation were assessed by net weight gain (NWG), feed intake (FI), specific growth rate (SGR), feed conversion ratio (FCR) and protein efficiency ratio (PER). Calculations were carried out using the following formulae: NWG = FW - IW; SGR = 100 ((ln FW - ln IW)/T); FCR = FI/WG; PER = WG/PI, where FW = final weight (g), IW = initial weight (g), T = duration of feeding (days), WG = wet weight gain (g), FI = feed intake (g) and PI = protein ingested (g). At the end of the trial four fish per tank were pooled

into two samples (thus $n = 4$) to determine final carcass composition. Proximate composition analysis was conducted according to AOAC protocols [21].

2.3 RT-PCR

The mid-intestine was sampled from four fish per tank ($n = 8$) for gene expression of caspase-3, PCNA, HSP70, TLR2, TGF β , IL-10, TNF α and IL-1 β after six weeks. Total RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's protocol as described in Rawling *et al.* [22] with the addition of an extra isopropanol step. RNA concentration and purity was measured spectrophotometrically (NanoDrop Technologies) and RNA integrity was checked by running each sample on a 1% agarose gel. Any samples with DNA contamination were cleaned using RNeasy MiniElute Cleanup Kit (Qiagen). RNA samples were subsequently stored at -80°C until use.

A total concentration of 1 μ g of RNA was used for cDNA synthesis using iScript cDNA Synthesis Kit (BioRad) according to manufacturer's instructions. Primer efficiencies were determined using serial 1/10 dilutions of pooled cDNA and resulting plots of Ct versus the logarithmic cDNA input, using the equation $E = 10^{(-1/\text{slope})}$. Primer sequences and efficiencies are reported in Table 3. PCR reactions were run in duplicate (total reaction volume = 7.5 μ l) were set on a 384-well plate and each reaction consisted of 2 μ l of cDNA (1/10 dilution), 3.75 μ l of 2X concentrated SYBR Green Supermix (Biorad), 0.225 μ l of each forward and reverse primers (0.3 μ M) and 1.3 μ l of DEPC treated water (Ambion). All quality control measures and RT-reactions were carried out according to the MIQE guidelines [23]. The thermal profile for all reactions were 10 min at 95°C and then 40 cycles of 15s at 95°C and 60s at 60°C. Fluorescence monitoring occurred at the end of each cycle and melt curve analyses were performed in all cases to check for a single peak. GAPDH, β -actin and EF1- α

were all assessed as reference genes. Reference genes were imported into GeNorm (v 3.4, Center for Medical Research, Ghent University, Belgium) to assess the optimal number, and choices of reference genes. Experimental treatments were each compared to the control and analysed using the relative expression software tool (REST[®]) [24] and reported as fold change.

2.4 Intestinal histology

Four tilapia per tank were sampled at week six ($n = 8$) for histological appraisal of the mid-intestine. Tissue samples were fixed in 10% formalin and transferred to 70% ethanol after 48 hours. Samples were then dehydrated in graded ethanol concentrations prior to embedding in paraffin wax. In each specimen, multiple sections (5 μ m) were stained with haematoxylin and eosin (H & E) and Alcian Blue-PAS to assess the intestinal perimeter ratio (arbitrary units; AU) after Dimitroglou *et al.* [25], intraepithelial leucocytes (IEL's) levels and goblet cell abundance in the epithelium. IEL's and goblet cells were counted across a standardized distance of 100 μ m and then calculated by averaging the cell numbers from all samples within each treatment. All light microscopy images were analysed with Image J 1.46r (National Institute of Health, USA).

2.5 Intestinal microbiological analyses

After the experimental period, four fish per tank were euthanized by overdose (300mg l⁻¹) of tricaine methane sulphonate (MS222; Pharmaq, Fordingbridge, UK). The GI tract was aseptically removed in its entirety. Faecal matter from the mid-intestine was isolated, and pooled between two fish (thus $n = 4$ per treatment) to assess allochthonous bacterial

populations. Intestinal samples were either used immediately for culture based analysis or stored at -20°C for culture independent analysis.

2.5.1 Culture dependent analysis

Samples were serially diluted with PBS and 20µl was spotted onto duplicate MRS agar, Slanetz and Bartley and *Bacillus* selective media using the Miles and Misra method [26] to assess the allochthonous presumptive probiotic bacterial populations. Tryptone soya agar (TSA) was used to determine the total aerobic heterotrophic bacterial populations. Plates were incubated for 48 hours at 28°C and colony forming units (CFU g⁻¹) were calculated by counting colonies from statistically viable plates (between 3-30 colonies). Representative subsets of the presumptive probiotics were identified by using 16S rRNA gene sequence analysis using the protocol described in Ferguson et al. [27].

2.5.2 Culture independent analysis

At week six, digesta samples ($n = 4$) were used for culture independent analyses. DNA was extracted using the QIAamp Stool Mini Kit (Qiagen) with a lysozyme pre-treatment (50 mg mL⁻¹ in TE buffer for 30 min at 37°C) and a phenol-chloroform clean up, as described [28]. PCR amplification of the 16S rRNA V3 region was conducted using the reverse primer P2 and the forward primer P3 [29]. A 40-60% DGGE was performed, and presumptive probiotic bands extracted, using a DCode Universal Mutation Detection System (Bio-Rad laboratories, Italy) according to Merrifield et al [30]. The presumptive probiotic nucleotide sequences were submitted to a BLAST search to retrieve the closest known alignment identities.

2.6 Statistical analyses

All data are presented as means $\pm$ standard deviation. All data were checked for normality and analysed using ANOVA with *post-hoc* Tukey's HSD test (Statgraphics Centurion XVI, Warrenton, VA, USA). Where data were not normally distributed, data were analysed using a Kruskal- Wallis test with *post-hoc* Mann-Whitney U-tests. RT-PCR data were analysed using REST[®] 2009 (Qiagen, Hilden, Germany). DGGE banding patterns were transformed into presence/ absence matrices based on band peak intensities (Quantity One[®] version 4.6.3, Bio-Rad Laboratories, CA, USA). Band intensities were measured (Quantity One[®] 1-D Analysis Software, Bio-Rad Laboratories Ltd., Hertfordshire, UK), and analysed using Primer V6 software (PRIMER-E Ltd, Ivybridge, UK). In all cases, significance was accepted at $P < 0.05$.

3 Results

3.1 Growth performance and carcass composition

Growth performance was assessed by means of routine growth and feed utilisation parameters after six weeks of feeding experimental feeding (Table 4). Tilapia fed the PRO-3 diet displayed the best growth performance. In this treatment the final weight, weight gain and SGR were significantly higher when compared to either CON or PRO-INI ($P = 0.019$, 0.014 and 0.021 , respectively). However, they did not significantly differ from treatments PRO-1.5 or PRO-PULSE. No differences in feed intake, PER or FCR were observed between any treatment ($P = 0.054$, 0.190 and 0.237 , respectively). Additionally, there were no significant differences in carcass proximal composition (Table 4).

3.2 RT-PCR

Relative intestinal gene expression of caspase-3, PCNA, HSP70, TLR2, TNF α , IL-1 β , IL-10 and TGF β were analysed. The largest fold change was observed in caspase-3 mRNA levels which were up-regulated approximately seven fold in PRO-3 when compared to the control group ($P = 0.001$). The gene expression of PCNA and HSP70 were six and three and half times higher in PRO-3, respectively, when compared to the control treatment ($P < 0.001$ and 0.028 respectively; Figure 1).

Further changes were observed for the immunity related genes (Figure 2). TLR2 mRNA expression was significantly up-regulated, more than four fold, in PRO-3 when compared to the control treatment ($P = 0.004$). The pro-inflammatory cytokine genes TNF α and IL-1 β were up-regulated three and five times, respectively, in the intestine of the PRO-3 fed fish compared to the CON fed fish ($P = 0.028$ and 0.003, respectively). Furthermore, tolerogenic cytokine IL-10 and TGF β mRNA levels were also up-regulated by approximately five and six fold, respectively, in PRO-3 when compared to the control treatment ($P = 0.005$ and 0.003, respectively).

There were no significant changes in gene expression between any of the investigated genes between treatments PRO-1.5, PRO-PULSE and PRO-INI when compared to the control treatment ($P > 0.05$).

3.3 Intestinal histology

Light microscopy was used to examine the perimeter ratio, IEL and goblet cell levels from the mid-intestine (Table 5). Fish from all dietary treatments had an intact epithelial barrier with extensive mucosal folds, abundant IEL's and numerous goblet cells. Tilapia in different

treatments showed altered perimeter ratios ($P = 0.007$). The highest perimeter ratio was recorded in PRO-INI which was significantly higher than PRO-1.5 but not CON, PRO-3 or PRO-PULSE. Perimeter ratio in PRO-3 was also significantly higher when compared to the lower probiotic dose, PRO-1.5. However, perimeter ratio remained unchanged between treatments PRO-1.5, CON, and PRO-PULSE. IEL and goblet cell abundance remained unchanged by dietary treatment in groups CON, PRO-1.5, PRO-PULSE and PRO-INI. However, IEL levels were significantly elevated in PRO-3 when compared to treatments CON, PRO-PULSE and PRO-INI ($P < 0.05$) but not PRO-1.5. PRO-3 also contained significantly larger populations of goblet cell when compared to all other treatments ($P < 0.001$; Table 5).

3.4 Culture dependent analysis

The effect of AquaStar® Growout treatment on the aerobic heterotrophic bacteria was determined using culture based methods (Table 6). No significant differences were observed in TVC levels between the treatments with allochthonous levels approximately $\log 6 \text{ CFU g}^{-1}$ for each treatment ($P = 0.993$). The highest LAB levels were observed in the digesta of PRO-3 fed tilapia, these were significantly higher than of CON and PRO-INI ($P = 0.006$). Similarly, PRO-3 resulted in the highest *Bacillus* levels which were significantly higher than those found in PRO-PULSE but not in other treatments ($P = 0.026$). LAB and *Bacillus* populations were not different in treatments CON, PRO-1.5, PRO-PULSE and PRO-INI. Furthermore, enterococci levels were significantly higher in PRO-3 when compared to CON, PRO-PULSE and PRO-INI. Despite being numerically higher, they were not different to enterococci levels recovered in PRO-1.5 digesta. Representative subsets of the presumptive probiotics were confirmed as the probiotics by 16S rRNA gene sequence analysis.

3.5 DGGE

The influence of dietary AquaStar® Growout on the intestinal microbial diversity in tilapia was investigated using DGGE after six weeks of feeding experimental diets. Presumptive probiotic bands were identified by migration to the same position as known *B. subtilis*, *E. faecium*, *L. reuteri* and *P. acidilactici* samples. These bands were also isolated from DGGE gels and subsequent sequencing confirmed the presence of all four probiotic species from AquaStar® Growout fingerprints; these were not detected in control sample fingerprints. Table 7 displays the microbial ecological parameters derived from the DGGE fingerprints. There were no significant differences between treatments with regards to number of OTU's (N), species richness or diversity indices ($P = 0.083$, 0.086 and 0.102 , respectively). Replicates from CON and PRO-PULSE showed the highest similarity percentage (SIMPER), this was significantly higher than replicates in PRO-1.5 but not those in PRO-3 or PRO-INI. Apart from PRO-1.5, all other treatments displayed no differences with regards to SIMPER analyses. ANOSIM revealed that the microbial communities within PRO-3 fed tilapia were significantly dissimilar to CON, PRO-PULSE and PRO-INI (53.35%, 58.25% and 58.10% dissimilar, respectively; $P = 0.03$) but not PRO-1.5 (34.54% dissimilar; $P = 0.23$). Additionally, the microbial community within PRO-1.5 was significantly dissimilar to the microbial community within the intestine of PRO-PULSE (40.33% dissimilar; $P = 0.03$). This can be visualised in Figure 3 where there is a clustering effect of the communities from the PRO-3 replicates. Replicates from treatments CON, PRO-PULSE and PRO-INI showed loose clustering with level of overlap between these three treatments. Two out of four replicates from PRO-1.5 show high similarity to those from PRO-3, whereas the remaining two replicates are more similar to the other treatments (Figure 3).

283 4 Discussion

284 The administration of AquaStar® Growout at 3g kg⁻¹ for six weeks resulted in improved
285 growth performance when compared to treatments CON or PRO-INI. AquaStar® Hatchery
286 (which contains a higher concentration of the same probiotic strains as AquaStar® Growout)
287 has previously been reported to improve growth performance of rainbow trout
288 (*Oncorhynchus mykiss*) [31]. Although there is no data regarding the growth promoting
289 effects of AquaStar® Growout in tilapia, dietary provision of *Bacillus* spp., *Enterococcus* spp.
290 and *Lactobacillus* spp., either singularly or in combination with other species have been
291 reported to improve tilapia growth performance indicators [2, 4-8, 32-35]. The mechanisms
292 which underpin these improvements are only partly described. Previous work on tilapia
293 suggests that Aquastar® Growout may increase the intestinal absorptive surface area by
294 improving the microvilli density and microvilli length [36]. Probiotics may also be important
295 in the production of digestive enzymes. Essa *et al.* [6] reported elevated intestinal amylase,
296 protease and lipase activities in tilapia supplemented with *B. subtilis* and/ or *L. rhamnosus*
297 and elevated intestinal protease activity in fish supplemented with *S. cerevisiae*.

298 Heat shock proteins have important roles in protein metabolism, protein folding, protein
299 chaperoning, mediating the repair and degradation of damaged proteins and are also involved
300 in generating an immune response [38]. Furthermore it has also been proposed that heat
301 shock proteins play important roles in the long term adaptation of animals to their
302 environments through genetic mechanisms [39]. Fish exhibiting higher HSP70 expression
303 may therefore be more able to generate an efficient immune response and also be more
304 tolerant to a wider range of environmental conditions. In the present study gene expression
305 analyses were used to elucidate the effect of the probiotic treatment on the mid-intestine at
306 the molecular level. Many authors have reported lower expression of HSP70 after probiotic
307 administration in fish [40-42] including tilapia [11]. Here, intestinal HSP70 gene expression

showed the opposite trend as it was significantly higher in PRO-3 when compared to the control. Using an *ex vivo* approach, Ren et al. [13] demonstrated that exposure to *Aeromonas hydrophila* did not cause an upregulation of HSP70 in the anterior or posterior intestine of tilapia. Conversely, the addition of *Lactobacillus plantarum*, as well as a mix of *A. hydrophila* and *L. plantarum* to the intestinal sac caused an upregulation of HSP70 [13]. Similar results were reported by Liu et al. [12] after the feeding hybrid tilapia, *O. niloticus* x *Oreochromis aureus*, diets supplemented with two *Lactobacillus* species. From their studies it was also evident that there appears to be a dosage, as well as temporal effect. For example, after 10 days of feeding on the probiotic diet, intestinal HSP70 was significantly up-regulated, down-regulated after 20 days and not different after 35 days when compared to the control treatment.

Caspase-3 and PCNA gene expression were both significantly up-regulated in PRO-3 when compared with the control group. Caspase-3 is part of the cysteine-aspartic acid protease family where it is activated by initiator caspases-8 or 9 resulting in programmed cell death (apoptosis). On the other hand, PCNA (proliferating cell nuclear antigen) is a marker for cell proliferation and is crucial for cellular and DNA replication. Organised apoptosis is essential for the health of the host since it results in the elimination of dangerous or damaged cells without causing an inflammatory response or tissue damage [43]. Since the GI tract is one of the key sites of interaction with the external environment [44] the intestine could be exposed to a number of opportunistic pathogens or chemical contaminants, especially in aquaculture where high stocking densities and water quality can be problematic. Therefore, both an elevated proliferative and apoptotic capacity is likely to be beneficial to the host.

The gut associated lymphoid tissue (GALT) in fish differs from their mammalian counterparts since fish lack Peyer's patches and mesenteric lymph nodes. Teleosts possess a more diffusely organised GALT which provides a physical, chemical and cellular barrier to

pathogenic invasion [9]. Similar to mammalian models, immune and epithelial cells within the GALT of fish express pattern recognition receptors (PRR's) including toll-like receptors (TLR's), which are sensitive to a number of pathogen associated molecular patterns (PAMP's). Upon ligation, a cascade effect is initiated through a series of adaptor proteins and transcription factors resulting in the transcription of important immune molecules such as cytokines, chemokines and defensins [9].

TLR2 gene expression was up-regulated in PRO-3 when compared with the control treatment. TLR2 is ligated by lipoteichoic acid (LTA), which is a major constituent in the cell wall of Gram-positive bacteria [45], such as those present in AquaStar[®] Growout. This up-regulation, induced by Gram-positive probiotics might be of particular importance because tilapia are susceptible to a number of Gram-positive infections, in particular *Streptococcus iniae* and *Streptococcus agalactiae*. Indeed, TLR2 was up-regulated in Mrigal carp (*Cirrhinus mrigala*) following *Streptococcus uberis* infection as well as *A. hydrophila* infection [46], another destructive pathogen in tilapia culture. It has been demonstrated that TLR's may have important roles to play in the probiotic modulation of the innate immune system in other fish species [17, 18]. Sun et al. [18] reported an upregulation in both TLR2 and TLR5 in grouper (*Epinephelus coioides*) after *Psychrobacter* sp. supplementation. Furthermore, the authors demonstrated a higher expression of pro-inflammatory genes IL-1 β and IL-8, and the anti-inflammatory gene TGF β after probiotic supplementation. The present study also reports higher gene expression of both pro-inflammatory cytokines (TNF α and IL-1 β) and anti-inflammatory cytokines (IL-10 and TGF β) after probiotic administration at 3g kg⁻¹ when compared to the control treatment. Here, despite the up-regulation of pro-inflammatory cytokines, there was no evidence of inflammation from histology examinations. It is possible that this was balanced by the up-regulation of anti-inflammatory cytokine gene expressions. Other authors have reported higher expression of pro-inflammatory cytokines in tilapia after

probiotic feeding [10-15]. It is postulated that the induction of pro-inflammatory cytokines improves immune readiness of the host. In support of this, disease resistance studies in tilapia have demonstrated that probiotics are able to increase the expression of TNF α and IL-1 β and consequently the tilapia survival levels were significantly higher when exposed to *A. hydrophila* [12, 15].

The current study also demonstrated that the probiotics also have anti-inflammatory signalling effects, by inducing the up-regulation of TGF β and IL-10. Naturally, anti-inflammatory cytokines will have an immune-suppressive effect on the host; this could be indicative of a tolerance mechanism where the host does not interpret the probiotic as a threat. This has been demonstrated in other fish studies where TGF β was up-regulated after probiotic administration [11, 12]. To the authors knowledge this is the first study to demonstrate probiotic modulation of IL-10 in the intestine of tilapia after probiotic feeding. However, similar results have been reported in rainbow trout after *L. plantarum* supplementation [47].

Histological analyses revealed significantly larger populations of IEL's in the mid-intestine of tilapia in PRO-3 when compared to treatments CON, PRO-PULSE or PRO-INI. Similar results have been obtained in other studies using tilapia fed diets supplemented with either *P. acidilactici* or *Lactobacillus rhamnosus* for six weeks and 30 days, respectively [10, 14]. Probiotic administration has led to increased IEL abundance in other commercially important fish species including European sea bass (*Dicentrarchus labrax*) and gilthead sea bream (*Sparus aurata*) [48, 49]. Whilst the type of IEL cannot be eluded to in this study, Picchietti et al. [49] characterised elevated T-cells and acidophilic granulocytes in the posterior intestine of European sea bass. These data suggest that probiotics not only act upon the innate immune system in fish, but may have important roles to play through adaptive immunity mechanisms too.

Whilst all fish displayed abundant goblet cells within the intestine, there were significantly larger populations in the mid-intestine of tilapia fed PRO-3 when compared to all other treatments. Intestinal mucus is vital to the defensive barrier, both physically and chemically, since it functions to trap and remove pathogens, preventing their attachment to the epithelia. Dietary applications of *L. rhamnosus* and *P. acidilactici* have also been reported to increase the number of goblet cells in the tilapia intestine [14, 50].

This study was successful in recovering each probiotic species from tilapia digesta, a requirement which is essential for any probiotic candidate. Furthermore, probiotic supplementation was capable of modulating the composition of intestinal microbiota. This supports a previous study which also reported the detection of these probiotic species, and modulation of the intestinal microbiota, of tilapia using DGGE and high-throughput sequencing [36].

In conclusion, under the current experimental conditions, the continuous supplementation of AquaStar® Growout at 3g kg⁻¹ can improve growth performance and elevate the intestinal immunological status in tilapia. The probiotic may act to augment mucosal tolerance mechanisms whilst creating a state of immune readiness, improved barrier function through the increase the number of goblet cells and IELs in the intestine, which may ultimately retard pathogen infection and translocation. Future studies should assess these using challenge trials.

Conflict of interest

The authors declare that there are no conflicts of interest that could have direct or potential influence or impart bias on the work.

406 *Acknowledgements*

407 This work was carried out as part of a PhD studentship which was jointly funded by
408 Plymouth University and Biomin GmbH (Herzogenburg, Austria). The authors would like to
409 thank Biomin GmbH for providing the materials for this research as well as their input with
410 regards to experimental design. Finally, the authors would like to thank all colleagues for
411 their assistance in the laboratory specifically Ben Eynon for his experience in fish husbandry
412 and Matthew Emery and Dr Ana Rodiles for their microbiological assistance.

413

414 **Figure 1:** Relative mid-intestinal gene expression of caspase-3 and PCNA and HSP70 after
415 six weeks of feeding experimental diets. Values are reported in fold change when compared
416 against the expression in the control treatment (set to 1.0). Asterisks highlight significant
417 differences ($P < 0.05$) when compared to the control treatment.

418

419 **Figure 2:** Relative gene expression of mid-intestinal TLR2 receptor (A) pro-inflammatory
420 cytokines TNF α (B) and IL-1 β (C) and anti-inflammatory cytokines TGF β (D) and IL-10 (E)
421 and after six weeks of feeding experimental diets. Values are reported in fold change when
422 compared against the expression in the control treatment (set to 1.0). Asterisks highlight
423 significant differences ($P < 0.05$) when compared to the control treatment.

424

425 **Figure 3:** nMDS plot showing similarity of the intestinal allochthonous microbiota of each
426 treatment after six weeks of feeding experimental diets. Lines represent different levels of
427 similarity.

428 **Table 1:** Dietary formulation and chemical composition (%).

	Basal	1.5g kg ⁻¹	3g kg ⁻¹
Fishmeal ^a	10.00	10.00	10.00
Soyabean meal ^b	33.89	33.89	33.89
Corn Starch ^c	31.90	31.75	31.60
Lysamine pea protein ^d	5.00	5.00	5.00
Glutalys ^d	10.00	10.00	10.00
Fish oil	3.75	3.75	3.75
Corn oil	4.00	4.00	4.00
Vitamin& mineral premix ^f	0.50	0.50	0.50
CMC-binder ^c	0.50	0.50	0.50
Methionine ^c	0.36	0.36	0.36
AquaStar [®] Growout ^g	0.00	0.15	0.30
<i>Proximate composition (% as fed basis)</i>			
Moisture	7.16 ± 0.03	5.89 ± 0.09	8.23 ± 0.19
Crude protein	37.57 ± 0.16	38.08 ± 0.30	37.03 ± 0.13
Lipid	10.09 ± 0.03	10.61 ± 0.24	10.41 ± 0.09
Ash	4.29 ± 0.04	4.25 ± 0.07	4.20 ± 0.01
Energy (MJ kg ⁻¹)	19.72 ± 0.05	19.57 ± 0.40	18.97 ± 0.19

429 ^a Herring meal LT92 – United Fish Products Ltd., Aberdeen, UK.

430 ^b Hamlet HP100, Denmark.

431 ^c Sigma- Aldrich Ltd., UK.

432 ^d Roquette Frères, France.

433 ^e Natural wheat bran, Holland & Barrett, UK.

434 ^f Premier nutrition vitamin/mineral premix contains: 121 g kg⁻¹ calcium, Vit A 1.0 µg kg⁻¹,
 435 Vit D3 0.1 µg kg⁻¹, Vit E (as alpha tocopherol acetate) 7.0 g kg⁻¹, Copper (as cupric sulphate)
 436 250 mg kg⁻¹, Magnesium 15.6 g kg⁻¹, Phosphorous 5.2 g kg⁻¹.

437 ^g Biomin Holding GmbH, Industriestrasse 21, 3130 Herzogenburg, Austria.

438

439

440

441

442

443

444 **Table 2:** Dietary codes used throughout the research article.

Dietary code	Diet
CON	Continuous feeding of basal diet (without probiotic)
PRO-1.5	Continuous feeding of the basal diet supplemented with AquaStar® Growout at 1.5g kg ⁻¹
PRO-3	Continuous feeding of the basal diet supplemented with AquaStar® Growout at 3g kg ⁻¹
PRO-PULSE	Alternating weekly between AquaStar® Growout feeding at 1.5g kg ⁻¹ and the basal diet
PRO-INI	Initial two weeks AquaStar® Growout feeding at 1.5g kg ⁻¹ followed by remainder of the trial on the basal diet

445 **Table 3:** Primer sequences used for RT-PCR

Gene	Forward 5' - 3'	Reverse 5' - 3'	Amplicon size	Tm (°C)	E-value	GenBank number
β -actin	TGACCTCACAGACTACCTCATG	TGATGTCACGCACGATTTCC	89	58.8	2.1	KJ126772.1
GAPDH	CCGATGTGTCAGTGGTGGAT	GCCTTCTTGACGGCTTCCTT	82	59.4	2.0	JN381952.1
EF1 α	TGATCTACAAGTGCGGAGGAA	GGAGCCCTTTCCCATCTCA	80	58.4	2.0	AB075952.1
Caspase-3	GGCTCTTCGTCTGCTTCTGT	GGGAAATCGAGGCGGTATCT	80	59.4	2.1	GQ421464.1
PCNA	CCCTGGTGGTGGAGTACAAG	AGAAGCCTCCTCATCGATCTTC	80	60.9	2.0	XM_003451046.2
HSP70	ACCCAGACCTTCACCACCTA	GTCCTTGGTCATGGCTCTCT	84	59.4	2.0	FJ213839.1
TLR2	GCAGTGCCTTGAGTCTTGATC	ACCGTGGAGATCGAGAACCT	101	59.6	2.1	XM_005460165
TNF α	CCAGAAGCACTAAAGGCGAAGA	CCTTGGCTTTGCTGCTGATC	82	59.9	2.0	AY428948.1
IL-1 β	TGGTGACTCTCCTGGTCTGA	GCACAACCTTTATCGGCTTCCA	86	58.7	2.1	XM_005457887.1
TGF β	GTTTGAACCTTCGGCGGTACTG	TCCTGCTCATAGTCCCAGAGA	80	59.8	2.1	XM_003459454.2
IL-10	CTGCTAGATCAGTCCGTCGAA	GCAGAACCGTGTCCAGGTAA	94	59.6	2.1	XM_003441366.2

446

447

448 **Table 4:** Growth performance and final carcass composition of tilapia after six weeks of feeding on experimental diets.

	CON	PRO-1.5	PRO-3	PRO-PULSE	PRO-INI
Initial weight (g fish ⁻¹)	29.42 ± 0.37	28.66 ± 0.25	29.10 ± 0.59	28.94 ± 0.03	29.42 ± 0.08
Average weight (g fish ⁻¹)	68.20 ± 0.63 ^a	68.83 ± 0.39 ^{ab}	71.74 ± 0.83 ^b	68.81 ± 0.04 ^{ab}	67.57 ± 1.34 ^a
Weight gain (g fish ⁻¹)	38.78 ± 0.10 ^a	40.17 ± 0.13 ^{ab}	42.64 ± 0.23 ^b	39.87 ± 0.06 ^{ab}	38.15 ± 1.42 ^a
Feed intake (g fish ⁻¹)	53.46 ± 1.23	55.39 ± 0.57	56.42 ± 0.70	55.42 ± 0.05	54.91 ± 0.04
PER	1.47 ± 0.15	1.47 ± 0.02	1.59 ± 0.02	1.44 ± 0.00	1.34 ± 0.10
FCR (g g ⁻¹)	1.38 ± 0.07	1.38 ± 0.01	1.33 ± 0.01	1.39 ± 0.00	1.44 ± 0.06
SGR (% day ⁻¹)	2.48 ± 0.06 ^a	2.58 ± 0.01 ^{ab}	2.66 ± 0.02 ^b	2.55 ± 0.01 ^{ab}	2.45 ± 0.06 ^a
Carcass proximate composition (%)					
Moisture	68.75 ± 0.44	68.97 ± 0.78	69.41 ± 0.89	69.81 ± 1.14	68.72 ± 0.59
Ash*	9.88 ± 0.37	10.17 ± 0.49	9.67 ± 0.31	10.52 ± 0.74	10.20 ± 0.08
Lipid*	34.68 ± 0.53	32.42 ± 0.78	34.94 ± 1.79	32.67 ± 1.68	33.78 ± 0.73
Protein*	52.03 ± 0.42	53.41 ± 0.52	52.48 ± 1.50	54.43 ± 1.32	52.90 ± 1.38
Energy* (MJ kg ⁻¹)	24.67 ± 0.17	24.39 ± 0.52	24.72 ± 0.53	24.56 ± 0.42	25.05 ± 0.19

449 * Parameters reported as percentage of dry weight matter.

450 ^{a, b} Different superscripts indicate a significant difference ($P < 0.05$).

Table 5: Histological data from the mid-intestine of tilapia fed control and AquaStar[®] Growout supplemented diets after six weeks of feeding on experimental diets.

	CON	PRO-1.5	PRO-3	PRO-PULSE	PRO-INI
Perimeter ratio (AU)	2.57 ± 0.58^{ab}	2.03 ± 0.29^a	3.16 ± 0.86^b	2.94 ± 0.47^{ab}	3.68 ± 0.72^b
IEL's (per 100 μm)	34.04 ± 4.41^a	37.39 ± 3.60^{ab}	41.63 ± 2.66^b	34.85 ± 2.99^a	31.95 ± 1.61^a
Goblet cells (per 100 μm)	4.96 ± 1.53^a	4.95 ± 0.91^a	8.56 ± 0.82^b	5.18 ± 0.64^a	5.58 ± 1.33^a

^{a, b} Different superscripts indicate a significant difference ($P < 0.05$).

Table 6: Allochthonous TVC, LAB, enterococci and *Bacillus* spp. (log CFU g⁻¹) in the intestinal tract of tilapia after six weeks of feeding on experimental diets.

	CON	PRO-1.5	PRO-3	PRO-PULSE	PRO-INI
TVC	5.89 ± 0.59	5.92 ± 0.27	5.94 ± 0.28	6.01 ± 0.53	6.05 ± 0.51
LAB	1.08 ± 1.34 ^a	3.30 ± 1.86 ^{ab}	5.39 ± 0.83 ^b	2.45 ± 2.18 ^{ab}	n.d ^a
<i>Bacillus</i> spp.	4.30 ± 0.25 ^{ab}	4.57 ± 0.22 ^{ab}	5.18 ± 0.58 ^b	3.87 ± 0.43 ^a	4.10 ± 0.45 ^{ab}
Enterococci	n.d ^a	3.13 ± 1.72 ^{bc}	5.03 ± 0.99 ^c	0.94 ± 1.12 ^{ab}	n.d ^a

n.d = not detected

^{a, b} Different superscripts indicate a significant difference ($P < 0.05$).

Table 7: Microbial community analysis of the intestinal allochthonous bacterial populations of tilapia from DGGE fingerprints after six weeks of feeding on experimental diets.

	Microbial ecological parameters				Similarity (ANOSIM)		
	<i>N</i>	Richness	Diversity	SIMPER (%)	<i>R</i> - value	<i>P</i> - value	Dissimilarity (%)
CON	17.75 ± 1.64	5.82 ± 0.39	2.87 ± 0.10	84.14 ± 7.35 ^a			
PRO-1.5	15.25 ± 4.87	5.19 ± 1.19	2.67 ± 0.34	62.54 ± 15.42 ^b			
PRO-3	13.00 ± 1.00	4.68 ± 0.25	2.56 ± 0.08	78.36 ± 8.88 ^{ab}			
PRO-PULSE	19.25 ± 2.49	6.16 ± 0.57	2.95 ± 1.13	82.42 ± 4.37 ^a			
PRO-INI	15.00 ± 1.41	5.17 ± 0.34	2.70 ± 0.09	72.81 ± 12.24 ^{ab}			
Pairwise comparisons							
CON vs PRO-1.5					0.27	0.09	35.11
CON vs PRO-3					1.00	0.03	53.35
CON vs PRO-PULSE					0.37	0.06	20.84
CON vs PRO-INI					0.17	0.11	23.64
PRO-1.5 vs PRO-3					0.15	0.23	34.54
PRO-1.5 vs PRO-PULSE					0.47	0.03	40.33
PRO-1.5 vs PRO-INI					0.44	0.06	42.48
PRO-3 vs PRO-PULSE					1.00	0.03	58.25
PRO-3 vs PRO-INI					0.98	0.03	58.10
PRO-PULSE vs PRO-INI					0.08	0.37	22.14

N = number of operational taxonomic units; Richness = Margalef species richness; Diversity = Shannon's diversity index; SIMPER = similarity percentage within group replicates.

^{a, b} Different superscripts indicate a significant difference ($P < 0.05$).

References

1. FAO. The State of World Fisheries and Aquaculture 2014. Food Agricultural Organization United Nations.; 2014.
2. El-Haroun ER, Goda AMAS, Kabir Chowdhury MA. Effect of dietary probiotic Biogen® supplementation as a growth promoter on growth performance and feed utilization of Nile tilapia *Oreochromis niloticus* (L.). Aquac Res. 2006 37:1473-80.
3. Abdel-Tawwab M, Abdel-Rahman AM, Ismael NEM. Evaluation of commercial live bakers' yeast, *Saccharomyces cerevisiae* as a growth and immunity promoter for Fry Nile tilapia, *Oreochromis niloticus* (L.) challenged *in situ* with *Aeromonas hydrophila*. Aquaculture. 2008 280:185-9.
4. Wang Y-B, Tian Z-Q, Yao J-T, Li W-f. Effect of probiotics, *Enterococcus faecium*, on tilapia (*Oreochromis niloticus*) growth performance and immune response. Aquaculture. 2008 277:203-7.
5. Apún-Molina JP, Santamaría- Miranda A, Luna-González A, Martínez-Díaz SF, Rojas-Contreras M. Effect of potential probiotic bacteria on growth and survival of tilapia *Oreochromis niloticus* L., cultured in the laboratory under high density and suboptimum temperature. Aquac Res. 2009 40:887-94.
6. Essa M, El-Serafy S, El-Ezabi M, Davboor S, Esmael N, Lall S. Effect of different dietary probiotics on growth, feed utilization and digestive enzymes activities of Nile tilapia, *Oreochromis niloticus*. J Arabian Aquac Soc. 2010 5:143-61.
7. Zhou X, Tian Z, Wang Y, Li W. Effect of treatment with probiotics as water additives on tilapia (*Oreochromis niloticus*) growth performance and immune response. Fish Physiol Biochem. 2010 36:501-9.
8. Ayyat MS, Labib HM, Mahmoud HK. A probiotic cocktail as a growth promoter in Nile tilapia (*Oreochromis niloticus*). J Appl Aquac. 2014 26:208-15.

9. Foey A, Picchietti S. Immune defences of teleost fish. Chichester: John Wiley & Sons Ltd; 2014.
10. Pirarat N, Pinpimai K, Endo M, Katagiri T, Ponpornpisit A, Chansue N, et al. Modulation of intestinal morphology and immunity in Nile tilapia (*Oreochromis niloticus*) by *Lactobacillus rhamnosus* GG. Res Vet Sci. 2011 91:e92-e7.
11. He S, Zhang Y, Xu L, Yang Y, Marubashi T, Zhou Z, et al. Effects of dietary *Bacillus subtilis* C-3102 on the production, intestinal cytokine expression and autochthonous bacteria of hybrid tilapia *Oreochromis niloticus* ♀; *Oreochromis aureus* ♂. Aquaculture. 2013 412–413:125-30.
12. Liu W, Ren P, He S, Xu L, Yang Y, Gu Z, et al. Comparison of adhesive gut bacteria composition, immunity, and disease resistance in juvenile hybrid tilapia fed two different *Lactobacillus* strains. Fish Shellfish Immunol. 2013 35:54-62.
13. Ren P, Xu L, Yang Y, He S, Liu W, Ringø E, et al. *Lactobacillus plantarum* subsp. *plantarum* JCM 1149 vs. *Aeromonas hydrophila* NJ-1 in the anterior intestine and posterior intestine of hybrid tilapia *Oreochromis niloticus* ♀ × *Oreochromis aureus* ♂: An *ex vivo* study. Fish Shellfish Immunol. 2013 35:146-53.
14. Standen BT, Rawling MD, Davies SJ, Castex M, Foey A, Gioacchini G, et al. Probiotic *Pediococcus acidilactici* modulates both localised intestinal- and peripheral-immunity in tilapia (*Oreochromis niloticus*). Fish Shellfish Immunol. 2013 35:1097-104.
15. Villamil L, Reyes C, Martínez-Silva MA. In vivo and in vitro assessment of *Lactobacillus acidophilus* as probiotic for tilapia (*Oreochromis niloticus*, Perciformes:Cichlidae) culture improvement. Aquac Res. 2014 45:1116-25.
16. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat Rev Immunol. 2010 10:735-44.

17. Abid A, Davies SJ, Wainess P, Emery M, Castex M, Gioacchini G, et al. Dietary synbiotic application modulates Atlantic salmon (*Salmo salar*) intestinal microbial communities and intestinal immunity. *Fish Shellfish Immunol.* 2013 35:1948-56.
18. Sun Y-Z, Xia H-Q, Yang H-L, Wang Y-L, Zou W-C. TLR2 signaling may play a key role in the probiotic modulation of intestinal microbiota in grouper *Epinephelus coioides*. *Aquaculture.* 2014 430:50-6.
19. Merrifield DL, Dimitroglou A, Foey A, Davies SJ, Baker RTM, Børgwald J, et al. The current status and future focus of probiotic and prebiotic applications for salmonids. *Aquaculture.* 2010 302:1-18.
20. NRC. Nutrient Requirements of Fish and Shrimp. Washington: The National Academies Press. 2011:376.
21. AOAC. Association Official Analytical Chemists (AOAC). (1995) *Official Methods of Analysis*. Association of Official Analytical Chemists. Arlington, VA; 1995.
22. Rawling MD, Merrifield DL, Kühlwein H, Snellgrove D, Gioacchini G, Carnevali O, et al. Dietary modulation of immune response and related gene expression profiles in mirror carp (*Cyprinus carpio*) using selected exotic feed ingredients. *Aquaculture.* 2014 418–419:177-84.
23. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem.* 2009 55:611-22.
24. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res.* 2002 30:e36.
25. Dimitroglou A, Merrifield D, Moate R, Davies S, Spring P, Sweetman J, et al. Dietary mannan oligosaccharide supplementation modulates intestinal microbial ecology and

improves gut morphology of rainbow trout, *Oncorhynchus mykiss* (Walbaum). J Anim Sci. 2009 87:3226-34.

26. Miles A, Misra S, Irwin J. The estimation of the bactericidal power of the blood. J Hyg. 1938 38:732-49.

27. Ferguson RMW, Merrifield DL, Harper GM, Rawling MD, Mustafa S, Picchietti S, et al. The effect of *Pediococcus acidilactici* on the gut microbiota and immune status of on-growing red tilapia (*Oreochromis niloticus*). J Appl Microbiol. 2010 109:851-62.

28. Al-Hisnawi A, Ringø E, Davies SJ, Wainnes P, Bradley G, Merrifield DL. First report on the autochthonous gut microbiota of brown trout (*Salmo trutta* Linnaeus). Aquac Res. 2014 46: 2962-2971.

29. Muyzer G, De Waal EC, Uitterlinden AG. Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol. 1993 59:695-700.

30. Merrifield DL, Güroy D, Güroy B, Emery MJ, Llewellyn CA, Skill S, et al. Assessment of *Chlorogloeopsis* as a novel microbial dietary supplement for red tilapia (*Oreochromis niloticus*). Aquaculture. 2010 299:128-33.

31. Giannenas I, Karamaligas I, Margaroni M, Pappas I, Mayer E, Encarnação P, et al. Effect of dietary incorporation of a multi-strain probiotic on growth performance and health status in rainbow trout (*Oncorhynchus mykiss*). Fish Physiol Biochem. 2015 41:119-28.

32. Lara-Flores M, Olvera-Novoa MA, Guzmán-Méndez BzE, López-Madrid W. Use of the bacteria *Streptococcus faecium* and *Lactobacillus acidophilus*, and the yeast *Saccharomyces cerevisiae* as growth promoters in Nile tilapia (*Oreochromis niloticus*). Aquaculture. 2003 216:193-201.

33. Mehrim A. Effect of dietary supplementation of Biogen (commercial probiotic) on mono-sex Nile tilapia *Oreochromis niloticus* under different stocking densities. Journal of Fisheries Aquat Sci. 2009 4:261-73.

34. Jatobá A, Vieira Fd, Buglione-Neto C, Mouriño' J, Silva BC, Seiftter W, et al. Diet supplemented with probiotic for Nile tilapia in polyculture system with marine shrimp. *Fish Physiol Biochem*. 2011 37:725-32.
35. Abumourad I, Abbas W, Awaad E, Authman M, El-Sahfei K, Sharaf O, et al. Evaluation of *Lactobacillus plantarum* as a probiotic in aquaculture: Emphasis on growth performance and innate immunity. *J Appl Sci Res*. 2013 9:572-82.
36. Standen BT, Rodiles A, Peggs DL, Davies SJ, Santos GA, Merrifield DL. Modulation of the intestinal microbiota and morphology of tilapia, *Oreochromis niloticus*, following the application of a multi-species probiotic. *Appl Microbiol Biotechnol*. 2015 99: 8403-8417.
37. Aly SM, Abdel-Galil Ahmed Y, Abdel-Aziz Ghareeb A, Mohamed MF. Studies on *Bacillus subtilis* and *Lactobacillus acidophilus*, as potential probiotics, on the immune response and resistance of *Tilapia nilotica* (*Oreochromis niloticus*) to challenge infections. *Fish Shellfish Immunol*. 2008 25:128-36.
38. Norouzitallab P, Baruah K, Muthappa DM, Bossier P. Non-lethal heat shock induces HSP70 and HMGB1 protein production sequentially to protect *Artemia franciscana* against *Vibrio campbellii*. *Fish Shellfish Immunol*. 2015 42:395-9.
39. Basu N, Todgham AE, Ackerman PA, Bibeau MR, Nakano K, Schulte PM, et al. Heat shock protein genes and their functional significance in fish. *Gene*. 2002 295:173-83.
40. Avella MA, Gioacchini G, Decamp O, Makridis P, Bracciatelli C, Carnevali O. Application of multi-species of *Bacillus* in sea bream larviculture. *Aquaculture*. 2010 305:12-9.
41. Avella MA, Olivotto I, Silvi S, Carnevali O. Effect of dietary probiotics on clownfish: a molecular approach to define how lactic acid bacteria modulate development in a marine fish. *Am J of Physiol-Reg I*. 2010 298:R359-R71.

42. Avella MA, Olivotto I, Silvi S, Ribecco C, Cresci A, Palermo F, et al. Use of *Enterococcus faecium* to improve common sole (*Solea solea*) larviculture. *Aquaculture*. 2011 315:384-93.
43. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. *Nature*. 1997 390:350-1.
44. Ringø E, Myklebust R, Mayhew TM, Olsen RE. Bacterial translocation and pathogenesis in the digestive tract of larvae and fry. *Aquaculture*. 2007 268:251-64.
45. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. *Immunity*. 1999 11:443-51.
46. Basu M, Swain B, Sahoo B, Maiti N, Samanta M. Induction of toll-like receptor TLR2, and MyD88-dependent TLR- signaling in response to ligand stimulation and bacterial infections in the Indian major carp, mrigal (*Cirrhinus mrigala*). *Mol Biol Rep*. 2012 39:6015-28.
47. Perez-Sanchez T, Balcazar JL, Merrifield DL, Carnevali O, Gioacchini G, De Blas I, et al. Expression of immune-related genes in rainbow trout (*Oncorhynchus mykiss*) induced by probiotic bacteria during *Lactococcus garvieae* infection. *Fish Shellfish Immunol*. 2011 31:196-201.
48. Salinas I, Abelli L, Bertoni F, Picchietti S, Roque A, Furones D, et al. Monospecies and multispecies probiotic formulations produce different systemic and local immunostimulatory effects in the gilthead seabream (*Sparus aurata* L.). *Fish Shellfish Immunol*. 2008 25:114-23.
49. Picchietti S, Fausto AM, Randelli E, Carnevali O, Taddei AR, Buonocore F, et al. Early treatment with *Lactobacillus delbrueckii* strain induces an increase in intestinal T-cells and granulocytes and modulates immune-related genes of larval *Dicentrarchus labrax* (L.). *Fish Shellfish Immunol*. 2009 26:368-76.

50. Pirarat N, Kobayashi T, Katagiri T, Maita M, Endo M. Protective effects and mechanisms of a probiotic bacterium *Lactobacillus rhamnosus* against experimental *Edwardsiella tarda* infection in tilapia (*Oreochromis niloticus*). Vet Immunol Immunop. 2006 113:339-47.

Highlights for manuscript “Dietary administration of a commercial mixed-species probiotic improves growth performance and modulates the intestinal immunity of tilapia, *Oreochromis niloticus*”

- AquaStar® Growout improves the growth performance of juvenile tilapia.
- AquaStar® Growout can augment mucosal tolerance.
- AquaStar® Growout improves immune readiness.